Company profile PCVX

Vaxcyte Inc
sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax’s lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax’s broad-...spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe Show More
Quarter analysis & expected interestLast update: February 09 2024 19:12:41.

After 39 days of this quarter the interest is at 88.0. Based on that we can calculate that during remaining 52 days it will total up to 205.0.
Vaxcyte stock expected interest is significantly higher compared to previous quarter (+606.9%) and same quarter last year (+109.2%).

YearQ1Q2Q3Q4
201954
80
48.1% QoQ
66
-17.5% QoQ
24
-63.6% QoQ
2020 32
-40.7% YoY 33.3% QoQ
201
151.2% YoY 528.1% QoQ
141
113.6% YoY -29.9% QoQ
80
233.3% YoY -43.3% QoQ
2021 26
-18.8% YoY -67.5% QoQ
27
-86.6% YoY 3.8% QoQ
23
-83.7% YoY -14.8% QoQ
54
-32.5% YoY 134.8% QoQ
2022 91
250.0% YoY 68.5% QoQ
217
703.7% YoY 138.5% QoQ
151
556.5% YoY -30.4% QoQ
223
313.0% YoY 47.7% QoQ
2023 98
7.7% YoY -56.1% QoQ
237
9.2% YoY 141.8% QoQ
141
-6.6% YoY -40.5% QoQ
29
-87.0% YoY -79.4% QoQ
2024 88
-10.2% YoY 203.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Vaxcyte stock search interestLast update: February 09 2024 19:12:40.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 19:12:43.

The average 5 years interest of Vaxcyte stock was 7.98 per week.
The last year interest of Vaxcyte stock compared to the last 5 years has changed by 29.95%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 128.41%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Vaxcyte vaccine to provide analysis

Correlation between past revenue and Vaxcyte vaccine search interest

There is not enough data for Vaxcyte vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Vaxcyte vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Vaxcyte pneumococcal vaccine to provide analysis

Correlation between past revenue and Vaxcyte pneumococcal vaccine search interest

There is not enough data for Vaxcyte pneumococcal vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Vaxcyte pneumococcal vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Vaxcyte bacterial diseases to provide analysis

Correlation between past revenue and Vaxcyte bacterial diseases search interest

There is not enough data for Vaxcyte bacterial diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Vaxcyte bacterial diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VAX-24 vaccine to provide analysis

Correlation between past revenue and VAX-24 vaccine search interest

There is not enough data for VAX-24 vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VAX-24 vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VAX-31 vaccine to provide analysis

Correlation between past revenue and VAX-31 vaccine search interest

There is not enough data for VAX-31 vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VAX-31 vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VAX-A1 vaccine to provide analysis

Correlation between past revenue and VAX-A1 vaccine search interest

There is not enough data for VAX-A1 vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VAX-A1 vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VAX-PG vaccine to provide analysis

Correlation between past revenue and VAX-PG vaccine search interest

There is not enough data for VAX-PG vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VAX-PG vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for VAX-GI vaccine to provide analysis

Correlation between past revenue and VAX-GI vaccine search interest

There is not enough data for VAX-GI vaccine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for VAX-GI vaccine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for PCVX
Earnings date: 2024-02-26 After close
Company name: Vaxcyte Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-12T10:57:26.675990939Z

Analyst Upgrades
Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target

2026-10-09T13:05:00-07:00

GlobeNewswire
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

2026-10-06T19:48:37-07:00

GlobeNewswire
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

2026-10-05T17:39:33.53431801Z

Analyst Upgrades
BTIG Reiterates Buy on Vaxcyte, Maintains $89 Price Target

2026-10-05T17:26:56.923277947Z

Analyst Upgrades
Needham Maintains Buy on Vaxcyte, Raises Price Target to $122

2026-10-05T12:53:26.042747138Z

Analyst Upgrades
Guggenheim Maintains Buy on Vaxcyte, Raises Price Target to $125

2026-10-05T08:00:00-04:00

Earnings Call Transcripts
VAX-31 OPUS-1 Adult Phase 3 Trial: Topline Results Conference Call - VAXCYTE INC

2026-09-28T17:23:08.95058865Z

Analyst Upgrades
B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130

2026-09-25T10:15:43.288382521Z

Analyst Upgrades
Needham Reiterates Buy on Vaxcyte, Maintains $110 Price Target

2026-09-03T13:05:00-07:00

GlobeNewswire
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

2026-08-27T13:05:00-07:00

GlobeNewswire
Vaxcyte to Participate in Upcoming Investor Conferences

2026-08-05T13:05:00-07:00

GlobeNewswire
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

2026-07-08T13:05:00-07:00

GlobeNewswire
Vaxcyte to Participate in Upcoming Investor Conferences

2026-06-02T20:05:00Z

GlobeNewswire
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

2026-05-06T20:05:00Z

GlobeNewswire
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update